La Jolla Pharmaceutical’s (Nasdaq: LJPC) experimental drug to treat a deadly blood pressure condition met its primary endpoint in a pivotal trial, the company announced today.
The Californian biopharmaceutical company is developing LJPC-501 (angiotensin II) to treat patients with catecholamine resistant hypotension, and this positive news sent the firm's shares skyrocketing 80.5% to $35.96 by late afternoon.
La Jolla said that the drug had achieved the study’s main goal of increasing blood pressure three hours after starting on the drug. In addition, a trend towards longer survival was observed, a 22% reduction in mortality risk through to day 28.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze